Overview

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Status:
Completed
Trial end date:
2017-08-29
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
Phase:
Phase 3
Details
Lead Sponsor:
Taro Pharmaceuticals USA